Fudan, Zhangjiang (688505.SH): Clinical trial of injecting FZ-P001 sodium for visualization of malignant lesions during surgery in patients with known or suspected lung cancer was accepted

Zhitong Finance App News, Fudan Zhangjiang (688505.SH) issued an announcement. The company recently received the “Notice of Acceptance” approved and issued by the State Drug Administration, and the Phase II clinical trial application for injecting FZ-P001 sodium to visualize malignant lesions during surgery in patients with known or suspected lung cancer was accepted.

Sodium FZ-P001 for injection is a new chemical class 1 compound independently developed by the company. It is an innovative photosensitizer. Its active ingredient is a folic acid receptor targeting small molecules conjugated with anthocyanin photosensitizers. It can target malignant tumor tissues with high expression of folic acid receptor α (FRα) and fluorescence imaging in the near-infrared region. The company plans to use the drug to develop intraoperative fluorescence guidance technology to indicate tissue residue and marginal state of malignant tumor lesions. The aim is to improve the surgical removal effect of related solid tumors (such as ovarian cancer, lung cancer, etc.), and to provide innovative solutions with both molecular targeting specificity and multi-dimensional biosensing for accurate navigation surgery in oncology surgery.